[{"indications": "Indications\u00a0\n(From Gonadotrophin-releasing hormone antagonists: British National Formulary)\nGonadotrophin-releasing hormone antagonists", "name": "DEGARELIX", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "8 Malignant disease and immunosuppression", "8.3 Sex hormones and hormone antagonists in malignant disease", "8.3.4 Hormone antagonists", "8.3.4.2 Gonadorelin analogues and gonadotrophin-releasing hormone antagonists", "Gonadotrophin-releasing hormone antagonists", "DEGARELIX"], "cautions": "Cautions\u00a0susceptibility to QT-interval prolongation\r\n(avoid concomitant use of drugs that prolong QT interval); monitor bone density; diabetes", "side-effects": "Side-effects\u00a0nausea; dizziness, headache, drowsiness, insomnia,\r\nasthenia; influenza-like symptoms; hot flushes, sweating (including\r\nnight sweats), weight gain; injection-site reactions; less\r\ncommonly diarrhoea, vomiting, abdominal discomfort, dry mouth,\r\nconstipation, anorexia, atrio-ventricular block, QT-interval prolongation,\r\nfainting, hypertension, hypersensitivity reactions, depression, anxiety,\r\noedema, gynaecomastia, micturition urgency, renal impairment, sexual\r\ndysfunction, pelvic pain, prostatitis, testicular pain, anaemia, musculoskeletal\r\npain, tinnitus, urticaria, alopecia, and rash", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/202691.htm", "doses": ["By subcutaneous injection into the abdominal\r\nregion, adult over 18 years, initially\r\n240\u00a0mg (administered as 2 injections of 120\u00a0mg), then 80\u00a0mg every\r\n28 days"]}]